No Data
The State Council meeting deployed to deepen the regulatory reform of Pharmaceutical and medical instruments, and Institutions indicated that there are significant structural opportunities in the Pharmaceutical Industry.
According to media reports, the recent State Council executive meeting deployed measures to deepen the regulation reform of pharmaceuticals and medical instruments, promoting the high-quality development of the pharmaceutical industry. Orient stated that looking back at 2024, the high base from the past has been digested, and the intra-hospital rigid demand is being released normally. Meanwhile, the Industry Chain of Innovative Drugs and the export of instruments continue to yield results, and the overall growth logic is clearly visible.
Lukang Pharma's Four Drugs Get Added to China's Centralized Procurement
Shandong Lukang Pharmaceutical (600789.SH): The company and its holding subsidiaries participate in the national pharmaceutical centralized procurement and are expected to win the bid.
On December 19, Gelonghui reported that Shandong Lukang Pharmaceutical (600789.SH) announced that the company and its controlling subsidiary, ShanDong Lukang Pharmaceutical Group Saiter Co., Ltd. (referred to as "Saiter Company"), participated in the bidding for the tenth nationwide centralized Pharmaceutical procurement organized by the Joint Procurement Office. The company and Saiter Company intend to have some of their Pharmaceuticals selected in this centralized procurement.
Is Shandong Lukang Pharmaceutical Co.,Ltd.'s (SHSE:600789) Latest Stock Performance A Reflection Of Its Financial Health?
Shandong Lukang Pharmaceutical (600789.SH) 2024 interim equity distribution: distributed 0.02 yuan per share, with the equity registration on December 17.
Shandong Lukang Pharmaceutical (600789.SH) announced the profit distribution plan for the first half of 2024, with this profit distribution based on the scheme...
Shandong Lukang Pharmaceutical Gets Approval for Anticoagulant for Knee, Hip Replacement Surgery
Is The Market Rewarding Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
